IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re | Patent A | pplication of | | · . | | | | | | | |
|--|--|---|------------------|------------------------------|--|--|--|--|--|--|--|
| SHIB | UYA, et | al. | Atty. Ref.: | 249-323 | | | | | | | |
| Seria | l No. | Unassigned | Group: | Unassigned | | | | | | | |
| Filed: | Ja | nuary 26, 2004 | Examiner: | Unassigned | | | | | | | |
| For: | SUBSTANCE WHICH INHIBITS BIDING OF INFORMATION TRANSFER MOLECULE FOR 1175-TYROSINE PHOSPHORYLATED KDR/FLK-1 AND USAGES OF THE SAME | | | | | | | | | | |
| * * * * * * * * * | | | | | | | | | | | |
| Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 | | | | | | | | | | | |
| Sir: | | | | | | | | | | | |
| | | INFORMATION DISCLOSURE | STATEMENT | _ | | | | | | | |
| | 1. | PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st of the second | • | on the merits] <i>N/C</i> | | | | | | | |
| | 2.(a) | Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C | | | | | | | | | |
| | 2 .(b) | (before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 | | | | | | | | | |
| | 3. | Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (Statement and Rule 17(p) fee), but before | • | | | | | | | | |
| | The fol | lowing are submitted in the above-identi | fied application | on in compliance with | | | | | | | |
| 37 C. | 37 C.F.R. §§ 1.97 and 1.98: | | | | | | | | | | |

SHIBUYA, et al. Se'rial No." Unassigned

| | 4. | A list of documents on Form PTO-1449. The listed documents are of record in the parent application Serial No. 09/969,037 such that further copies are not believed to be required. See, MPEP § 609. | | | | | |
|-------------|-------|--|--|--|--|--|--|
| This p | paper | s submitted in accordance with: | | | | | |
| \boxtimes | 5 | 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] | | | | | |
| | 6. | 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and | | | | | |
| | | a) The required Statement made in item 8 below; or | | | | | |
| | | b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. | | | | | |
| | 7. | 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement <u>and</u> Rule 17(p) fee), but before final fee payment]; and | | | | | |
| | | a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and | | | | | |
| | | b) The required Statement is stated in item 8 below. | | | | | |
| ☐ 8. | | Statement under 37 CFR 1.97(e) | | | | | |
| | | a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or | | | | | |
| | | b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. | | | | | |
| | 9. | Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of | | | | | |

SHIBUYA, et al. Serial No. Unassigned

this document are enclosed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

Sheet 1 of 1

| INFORM | MATION DISCLOSU | IRE ATTY, DOCKET NO. | | SERIAL NO. | | | | | | |
|---|--|----------------------|--|----------------------------|----------------|--------------------|-----------|--|--|--|
| | CITATION | 249-323 APPLICANT | | Unassigned | | | | | | |
| (Use | several sheets if necessary) | SHIBUYA, et al. | | GROUP | | | | | | |
| | | January 26, 2004 | | Unassigned | | | | | | |
| | | U.S. PA | ATENT DOCUMENTS | | | | DATE | | | |
| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING IF APPRO | | | | |
| | 5,766,860 | 06/1998 | TERMAN et al | | | | | | | |
| | 4,816,567 | 3/1989 | Cabilly | | | | | | | |
| | 4,543,439 | 9/1985 | Frackelton | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | FOREIG | N PATENT DOCUMENT | 'S | J | | | | | |
| | | | | - | | TRANSI | ATION | | | |
| | DOCUMENT | DATE | COUNTRY | CLASS | SUBCLASS | YES | NO | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | ling Author, Title, Date, | | | | | | | |
| | | | (DR Tyrosine Kinase as a Rec | | | | | | | |
| | | | Research Communications, V | | | | 36 | | | |
| | CUNNINGHAM, et al., "Interactions of FLT-1 and KDR with Phospholipase Cy: Identification of the Phosphotyrosine Binding Sites", Biochemical and Biophysical Research Communications, 240, pp. 635-639 (1997) | | | | | | | | | |
| | SAWANO, et al., "The | | d 1169-Tyrosine Containing R | | | | | | | |
| | | | nd Biophysical Research Con | | | | | | | |
| KINASHI, et al., "Receptor Tyrosine Kinase Stimulates Cell-Matrix Adhesion by Phosphatidylinosito and Phospholipase C-y1 Pathways", Blood, Vol. 86, No. 6 (1995), pp. 2086-2090 | | | | | | | | | | |
| | and Priospriolipase C | -yı Falliways , t | 51000, VOI. 66, NO. 6 (1995), F | р. 2080-2090 | | | | | | |
| | | | | ., . | | | | | | |
| | | | | | | | | | | |
| *Examiner | 1 | | Date Considered | | | | | | | |
| Examiner: Initia | | | ormance with MPEP 609; Draw line through | h citation if not in confo | rmance and not | considered. | Include | | | |
| copy of this for | n with next communication to applic | cation. | | | Form PTO-FB- | A820 (Also | PTO-1449) | | | |